Laparoscopic Surgery VS RFA for Recurrent HCC
Hepatocellular Carcinoma
About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Age 18-75 years;
- First recurrent HCC after curative hepatectomy;
- A solitary recurrent HCC ≤ 3.0 cm in diameter, or multiple recurrent HCC ≤ 3 lesions, each ≤ 3.0 cm in diameter;
- Tumor located in left lateral lobe (segment II or III) or subcapsule of liver(subcapsular nodule was defined as a lesion located less than 1 cm from the liver edge and could be treated by either LS or RFA.
- No radiologic evidence of invasion into major portal/ hepatic vein branches;
- No extrahepatic metastases;
- Child-Turcotte-Pugh class A or B;
Exclusion Criteria:
- Coagulation disorders (prothrombin activity <40% or a platelet count of <80,000/mm3);
- History of hepatic encephalopathy, ascites refractory to diuretics or esophageal or gastric variceal bleeding;
- History of a secondary malignancy;
- Severe dysfunction of the heart, kidney, or other organs
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
laparoscopic surgery(LS)
Radiofrequency ablation(RFA)
For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).